Empagliflozin (Jardiance) for Heart Failure

Date: November 16, 2020 Issue #:  1611Summary:  In a randomized, placebo-controlled trial, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance– Boehringer Ingelheim/Lilly) reduced the composite risk of cardiovascular death or hospitalization for worsening heart failure (HF) in patients with heart failure with reduced ejection fraction (HFrEF), whether or not they had type 2 diabetes. To date, empagliflozin has not been approved by the F DA for such use. The SGLT2 inhibitor dapagliflozin(Farxiga) was approved by the FDA for this indication earlier this year.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Source Type: research